Wyeth Looks To Pipeline And Cost Cuts As Generics Threaten Bottom Line
Executive Summary
Wyeth's authorized generic version of its blockbuster heartburn drug Protonix holds a meaningful share of that generic market, the firm announced in an April 22 sales and earnings call